期刊文献+

大剂量盐酸羟考酮缓释片治疗癌痛临床观察 被引量:7

Clinical Observation on High Doses of Oxycodone Hydrochloride Prolonged-release Tablets in Treatment With Cancer Pain
下载PDF
导出
摘要 目的探讨癌症患者发生癌痛时用大剂量盐酸羟考酮缓释片治疗的临床效果。方法选取2013年1月-2015年6月在本院进行治疗的60例癌痛患者,对其进行盐酸羟考酮缓释片止痛治疗,并根据患者每天癌痛次数进行计量调整。实验中发生爆发性疼痛时给予吗啡进行治疗。实验3周,进行疼痛评分、治疗效果以及不良反应的总结。结果有31例患者每天剂量为120-180 mg,有19例患者每天剂量为181-250 mg,有6例患者每天剂量为251-300 mg,有4例患者每天剂量大于301 mg。患者疼痛缓解率93.3%,不良反应率为45%。结论盐酸羟考酮缓释片缓解癌痛效果明显,尤其是大剂量应用时,能在短时间内解决患者癌痛困扰,并且安全性高。 Objective To investigate the clinical effect of high doses of oxycodone hydrochloride extended release tablets therapy for cancer pain in patients. Methods Chose 60 cases of patients with cancer pain in our hospital from January 2013 to June 2015,used sustained-release oxycodone hydrochloride tablets for treatment,and adjusted according to the measurement frequency in patients with cancer pain per day. Morphine when treating breakthroughpain occurs experiments. Three weeks,pain scores were summarized therapeutic effects and adverse reactions. Results 31 patients daily doses of 120- 180 mg,19 patients daily doses of 181 - 250 mg,6 patients a daily dose of 251 - 300 mg,4 patients daily doses greater than 301 mg. 93.3% of patients pain relieved,adverse reaction rate of 45%. Conclusion The sustained-release oxycodone hydrochloride tablets relieving pain effect is obvious,especially in large doses,in patients with cancer pain in a short time to solve problems,and is safe.
出处 《中国卫生标准管理》 2016年第18期105-107,共3页 China Health Standard Management
关键词 盐酸羟考酮缓释片 大剂量 癌痛 Oxycodone hydrochloride prolonged-release tablets High dosage Cancer pain
  • 相关文献

参考文献9

二级参考文献101

  • 1王萍,刘勇,汪涛,程宝智.盐酸羟考酮控释片治疗中重度癌痛疗效观察[J].现代肿瘤医学,2008,16(11):1983-1985. 被引量:18
  • 2严相默.术后镇痛进展[J].中国疼痛医学杂志,2004,10(6):360-364. 被引量:51
  • 3曹燕.决策分析模型在药物经济学中的应用[J].中国药房,2007,18(8):561-564. 被引量:32
  • 4余小红,吴定国,杨金凤,高敏.盐酸羟考酮控释片治疗癌痛疗效观察[J].中国医院药学杂志,2007,27(9):1277-1278. 被引量:17
  • 5汤钊猷.现代肿瘤学[M].3版.上海:复旦大学出版社,2011:890-931.
  • 6Treede RD, Jensen TS, Campbell JN, et al. Redefinition of neuropathic pain and a grading system for clinical use: consensus statement on clinical and research diagnostic criteria. Neurology, 2008, 70:1630 - 1635.
  • 7Hald A, Nedergaard S, Hansen R, et al. Differential acti- vation of spinal cord glial cells in murine models of neur- opathic and cancer pain. J Pain, 2009, 13:138 145.
  • 8Bennett MI, Rayment C, Hjermstad M, et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain, 2012, 153:359 - 365.
  • 9Paredes MG, Gonza" lez FM, Prado PM, et a/. First evid- ence of oncologic neuropathic pain prevalence after sere- ening 8615 cancer patients. Results of the on study. Ann Oncol, 2011, 22:924 - 930.
  • 10Russell portenoy for the ID pain Steering Committee. Development and testing of a neuropathic pain screen- ing questionnaire: ID Pain. Curr Med Res Opin, 2006, 22:1555 - 1565.

共引文献194

同被引文献56

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部